The Clinical and Economic Effects of Switching Medicare Beneficiaries with Type 2 Diabetes from Analog to Human Insulin

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 4-OR
Author(s):  
JING LUO ◽  
NAZLEEN F. KHAN ◽  
THOMAS MANETTI ◽  
JAMES J. ROSE ◽  
ANI KALOGHLIAN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Human Insulin ◽  
Economic Effects ◽  
Medicare Beneficiaries

scholarly journals Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes

JAMA ◽  
2019 ◽  
Vol 321 (4) ◽  
pp. 374 ◽  
Author(s):  
Jing Luo ◽  
Nazleen F. Khan ◽  
Thomas Manetti ◽  
Jim Rose ◽  
Ani Kaloghlian ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Human Insulin ◽  
Health Plan ◽  
Medicare Beneficiaries

Polymorphism in the 5'-flanking region of the human insulin gene and its possible relation to type 2 diabetes

Science ◽  
1981 ◽  
Vol 213 (4512) ◽  
pp. 1117-1120 ◽  
Author(s):  
P Rotwein ◽  
R Chyn ◽  
J Chirgwin ◽  
B Cordell ◽  
H. Goodman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Human Insulin ◽  
Insulin Gene ◽  
Human Insulin Gene ◽  
Flanking Region

scholarly journals α-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine

2021 ◽  
Vol 12 (16) ◽  
pp. 5853-5864
Author(s):  
Amber L. H. Gray ◽  
Aleksandra Antevska ◽  
Benjamin A. Link ◽  
Bryan Bogin ◽  
Susan J. Burke ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Protective Effect ◽  
Human Insulin ◽  
Human Amylin

CGRP concentration is elevated in migraine conditions. The protective effect of migraine against type 2 diabetes is attributed to the ability of CGRP to remodel human amylin aggregation and to suppress the secretion of mouse insulin 2 (the orthologue of human insulin).

Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus

2001 ◽  
Vol 134 (3) ◽  
pp. 203 ◽  
Author(s):  
William T. Cefalu ◽  
Jay S. Skyler ◽  
Ione A. Kourides ◽  
William H. Landschulz ◽  
Cecile C. Balagtas ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Human Insulin ◽  
Insulin Treatment

scholarly journals Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Diabetes Care ◽  
2010 ◽  
Vol 33 (6) ◽  
pp. 1288-1290 ◽  
Author(s):  
C. Kapitza ◽  
E. Zijlstra ◽  
L. Heinemann ◽  
M. C. Castelli ◽  
G. Riley ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Human Insulin ◽  
Oral Insulin ◽  
Regular Human Insulin

scholarly journals Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA

2021 ◽  
Author(s):  
HoJin Shin ◽  
Sebastian Schneeweiss ◽  
Robert J. Glynn ◽  
Elisabetta Patorno
Keyword(s):  
Type 2 Diabetes ◽  
Line Treatment ◽  
Medicare Beneficiaries ◽  
First Line ◽  
Adult Type ◽  
Antidiabetic Treatment ◽  
Glucagon Like Peptide 1 ◽  
Lowering Drug ◽  
First Line Treatment

<p>Objective: We evaluated recent utilization trends and predictors of first-line antidiabetic treatment in patients with type 2 diabetes.</p> <p>Research Design and Methods: Using two large U.S. health insurance databases (Clinformatics and Medicare), we identified adult type 2 diabetes patients who initiated antidiabetic treatment from 2013 through 2019. Quarterly trends in use of first-line antidiabetic treatment were plotted overall and stratified by cardiovascular disease (CVD). Multinomial logistic regressions were fit to estimate predictors of first-line antidiabetic treatment, using metformin, the recommended first-line treatment for type 2 diabetes, as the common referent.</p> <p>Results: Metformin was the most frequently initiated medication used by 80.6% of Medicare beneficiaries and 83.1% of commercially insured patients. Sulfonylureas were used by 8.7% (Medicare) and 4.7% (commercial). Both populations had low use of sodium-glucose cotransporter 2 inhibitors (SGLT-2i, 0.8% [Medicare] and 1.7% [commercial]) and glucagon-like peptide 1 receptor agonists (GLP-1RA, 1.0% [Medicare] and 3.5% [commercial]), with increasing trends over time (P < 0.01). Initiators of antidiabetic drugs with established cardiovascular benefits (SGLT-2i and GLP-1RA) were more likely to be younger, and had prevalent CVD or higher socioeconomic status compared with initiators of metformin. </p> <p>Conclusions: Among adult patients with type 2 diabetes, metformin was by far the most frequent first-line treatment. While the use of SGLT-2i and GLP-1RA was low from 2013 through 2019, it increased among patients with CVD.</p>

Sign in / Sign up

Export Citation Format

Share Document